Keywords: Benlysta manufacturing deal, Lonza, GlaxoSmithKline, Human Genme Sciences
Lonza to produce lupus drug Benlysta for GlaxoSmithKline/Human Genome Sciences
Article | 13 July 2010
Human Genome Sciences has entered into an agreement with Switzerland-based chemical company Lonza for the future commercial supply of Benlysta ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
